DECIBEL THERAPEUTICS INC's ticker is DBTX and the CUSIP is 24343R106. A total of 42 filers reported holding DECIBEL THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $12,087,787 | +27.5% | 3,139,685 | 0.0% | 66.30% | +480.1% |
Q1 2023 | $9,481,849 | +47.3% | 3,139,685 | 0.0% | 11.43% | +126.6% |
Q4 2022 | $6,436,354 | -40.7% | 3,139,685 | 0.0% | 5.04% | +6.3% |
Q3 2022 | $10,863,000 | -17.8% | 3,139,685 | 0.0% | 4.74% | -12.3% |
Q2 2022 | $13,218,000 | +38.5% | 3,139,685 | 0.0% | 5.41% | +108.7% |
Q1 2022 | $9,545,000 | -34.6% | 3,139,685 | 0.0% | 2.59% | -29.1% |
Q4 2021 | $14,600,000 | -39.7% | 3,139,685 | 0.0% | 3.65% | -20.5% |
Q3 2021 | $24,207,000 | -10.3% | 3,139,685 | 0.0% | 4.60% | -2.5% |
Q2 2021 | $27,001,000 | -24.3% | 3,139,685 | 0.0% | 4.71% | +4.5% |
Q1 2021 | $35,667,000 | – | 3,139,685 | – | 4.51% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
TRV GP III, LLC | 3,139,685 | $14,600,000 | 3.65% |
Samsara BioCapital, LLC | 826,422 | $3,843,000 | 0.75% |
Orbimed Advisors | 4,945,192 | $22,995,000 | 0.30% |
Alphabet Inc. | 1,636,258 | $7,609,000 | 0.18% |
Casdin Capital, LLC | 1,170,048 | $5,441,000 | 0.15% |
HARVARD MANAGEMENT CO INC | 328,798 | $1,529,000 | 0.14% |
Bronte Capital Management Pty Ltd. | 157,216 | $731,000 | 0.05% |
ATLAS CAPITAL ADVISORS LLC | 41,025 | $190,766,000 | 0.03% |
SUVRETTA CAPITAL MANAGEMENT, LLC | 263,600 | $1,226,000 | 0.02% |
Woodline Partners LP | 275,001 | $1,279,000 | 0.02% |